Business, energy, technology, markets and global industry news from Business News Today

antibody discovery

PharmaDeviceNews antibody discovery
Representative image of radiopharmaceutical preparation and PET imaging, illustrating how the Sanyou Bio and Baiyunshan Xihe collaboration aims to combine AI-led antibody discovery with nuclear medicine development for precision oncology.
Medical Devices & Diagnostics

AI meets nuclear medicine as Sanyou Bio and Baiyunshan Xihe pursue cancer diagnostics

Explore how Sanyou Bio and Baiyunshan Xihe are combining AI discovery and nuclear medicine to advance precision oncology theranostics.

Read More
Representative image: Biocytogen’s AAALAC accreditation highlights the growing importance of preclinical research quality, animal care standards and antibody drug discovery credibility in translational medicine.
Pharma & Biotech

Why Biocytogen’s Boston accreditation matters for antibody discovery partners

Find out how Biocytogen’s AAALAC accreditation could strengthen preclinical research credibility and partner confidence.

Read More
Representative biotech patent litigation image showing antibody discovery research, laboratory documents and legal symbols.
Pharma & Biotech

Could Harbour BioMed’s legal win reshape the economics of antibody drug discovery?

Read how Harbour BioMed’s Amgen patent win could reshape antibody discovery licensing, biologics IP and biotech investor sentiment.

Read More
Pharma & Biotech

Can RenSuper help Biocytogen reduce the bottlenecks in antibody development?

Biocytogen is turning antibody discovery into an AI-led industrial workflow. RenSuper could speed biologics R&D, but validation risk remains.

Read More
Features & Analysis

Drug discovery has an AI problem. Clicklinks thinks the answer is connection, not just algorithms

Find out how Sanyou Bio’s Clicklinks platform could reshape AI-led drug discovery by linking biotech, CRO, CDMO and preclinical resources.

Read More
Representative image of an AI-enabled biotechnology lab, illustrating how the LenioBio and Twist Bioscience partnership could accelerate protein expression, wet-lab validation, and next-generation AI drug discovery workflows.
Pharma & Biotech

AI can design proteins faster than labs can test them. LenioBio and Twist want to fix that bottleneck

AI can design proteins fast. Biology still sets the pace. LenioBio and Twist Bioscience are targeting drug discovery’s validation gap.

Read More
Pharma & Biotech

What the Invenra B-Body licensing deal changes for Twist Bioscience and antibody discovery services

Twist Bioscience licenses Invenra’s bispecific antibody platform. Find out how this reshapes biologics discovery infrastructure and industry dynamics.

Read More
Medical Devices & Diagnostics

Can Sanyou Biopharmaceuticals and KanryBio Biotechnology disrupt the global companion diagnostics market?

Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. and Wenzhou KanryBio Biotechnology Co., Ltd. have entered into a strategic collaboration focused on co-developing high-value reagents and products for biomarker assay kits. Announced on December 10, 2025, this partnership aims to combine Sanyou Biopharmaceuticals’ global leadership in AI-driven molecular discovery with KanryBio Biotechnology’s capabilities in kit product development and

Read More